InsiderTrades.com logo
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.
Rebecca Taub net worth and biography
  • Phone
  • Email
  • Website

Rebecca Taub Biography and Net Worth

Director, Founder, Chief Medical Officer and President of Research & Development of Madrigal Pharmaceuticals
Dr. Taub has more than 20 years of experience leading drug development, including roles as Senior Vice President of R&D at VIA Pharmaceuticals, Vice President of Metabolic Disease Research at Hoffmann-La Roche, and leadership roles at Bristol Myers Squibb and DuPont Pharmaceuticals. She was also tenured Professor of Genetics and Medicine at the University of Pennsylvania and a Howard Hughes Investigator.

What is Rebecca Taub's net worth?

The estimated net worth of Rebecca Taub is at least $107.17 million as of April 8th, 2024. Dr. Taub owns 458,999 shares of Madrigal Pharmaceuticals stock worth more than $107,171,677 as of September 22nd. This net worth estimate does not reflect any other assets that Dr. Taub may own. Additionally, Dr. Taub receives a salary of $939,830.00 as Director, Founder, Chief Medical Officer and President of Research & Development at Madrigal Pharmaceuticals. Learn More about Rebecca Taub's net worth.

How old is Rebecca Taub?

Dr. Taub is currently 72 years old. There are 5 older executives and no younger executives at Madrigal Pharmaceuticals. Learn More on Rebecca Taub's age.

What is Rebecca Taub's salary?

As the Director, Founder, Chief Medical Officer and President of Research & Development of Madrigal Pharmaceuticals, Inc., Dr. Taub earns $939,830.00 per year. Learn More on Rebecca Taub's salary.

How do I contact Rebecca Taub?

The corporate mailing address for Dr. Taub and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Rebecca Taub's contact information.

Has Rebecca Taub been buying or selling shares of Madrigal Pharmaceuticals?

Rebecca Taub has not been actively trading shares of Madrigal Pharmaceuticals in the last ninety days. Most recently, Rebecca Taub sold 2,676 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a transaction totalling $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company's stock, valued at $112,909,164.01. Learn More on Rebecca Taub's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 4 times. They purchased a total of 226,067 shares worth more than $43,382,043.47. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 188,584 shares worth more than $40,797,262.98. The most recent insider tranaction occured on September, 9th when CEO William John Sibold sold 6,363 shares worth more than $1,551,490.29. Insiders at Madrigal Pharmaceuticals own 23.9% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 9/9/2024.

Rebecca Taub Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Sell2,676$245.99$658,269.24458,999View SEC Filing Icon  
4/5/2024Sell27,506$243.36$6,693,860.16458,999View SEC Filing Icon  
4/3/2024Sell27,845$245.14$6,825,923.30458,999View SEC Filing Icon  
6/11/2018Sell73,526$287.46$21,135,783.96View SEC Filing Icon  
See Full Table

Rebecca Taub Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Rebecca Taub's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $233.49
Low: $233.00
High: $244.23

50 Day Range

MA: $255.47
Low: $233.00
High: $287.24

2 Week Range

Now: $233.49
Low: $119.76
High: $299.98

Volume

530,021 shs

Average Volume

440,606 shs

Market Capitalization

$4.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.